102 related articles for article (PubMed ID: 9850097)
1. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
Kam JL; Regimbald LH; Hilgers JH; Hoffman P; Krantz MJ; Longenecker BM; Hugh JC
Cancer Res; 1998 Dec; 58(23):5577-81. PubMed ID: 9850097
[TBL] [Abstract][Full Text] [Related]
2. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer.
Regimbald LH; Pilarski LM; Longenecker BM; Reddish MA; Zimmermann G; Hugh JC
Cancer Res; 1996 Sep; 56(18):4244-9. PubMed ID: 8797599
[TBL] [Abstract][Full Text] [Related]
3. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
4. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
5. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
6. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
7. Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody.
Baeckström D; Nilsson O; Price MR; Lindholm L; Hansson GC
Cancer Res; 1993 Feb; 53(4):755-61. PubMed ID: 7679050
[TBL] [Abstract][Full Text] [Related]
8. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
[TBL] [Abstract][Full Text] [Related]
9. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
10. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
Barratt-Boyes SM; Vlad A; Finn OJ
Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
[TBL] [Abstract][Full Text] [Related]
11. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1.
Shen Q; Rahn JJ; Zhang J; Gunasekera N; Sun X; Shaw AR; Hendzel MJ; Hoffman P; Bernier A; Hugh JC
Mol Cancer Res; 2008 Apr; 6(4):555-67. PubMed ID: 18403635
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
13. NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitution.
Sillerud LO; Burks EJ; Brown WM; Brown DC; Larson RS
J Pept Res; 2004 Oct; 64(4):127-40. PubMed ID: 15357668
[TBL] [Abstract][Full Text] [Related]
14. [Molecular biological analyses of mucin core proteins and their clinical application].
Hinoda Y; Imai K
Gan To Kagaku Ryoho; 1994 Feb; 21(2):150-6. PubMed ID: 8311484
[TBL] [Abstract][Full Text] [Related]
15. [New mucin core protein genes and their clinical application].
Imai K
Hokkaido Igaku Zasshi; 1996 Mar; 71(2):139-43. PubMed ID: 8641670
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antibody recognition of synthetic antigens from MUC1.
Bánóczi Z; Mezõ G; Windberg E; Uray K; Majer Z; Hudecz F
J Pept Sci; 2008 May; 14(5):610-6. PubMed ID: 17975847
[TBL] [Abstract][Full Text] [Related]
17. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
[TBL] [Abstract][Full Text] [Related]
18. MUC1 mucin core protein binds to the domain 1 of ICAM-1.
Hayashi T; Takahashi T; Motoya S; Ishida T; Itoh F; Adachi M; Hinoda Y; Imai K
Digestion; 2001; 63 Suppl 1():87-92. PubMed ID: 11173916
[TBL] [Abstract][Full Text] [Related]
19. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
20. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB.
Lin YC; Shun CT; Wu MS; Chen CC
Clin Cancer Res; 2006 Dec; 12(23):7165-73. PubMed ID: 17145842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
